ICU Medical Beheer

Beheer criteriumcontroles 2/4

De CEO ICU Medical is Vivek Jain, benoemd in Feb2014, heeft een ambtstermijn van 10.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.81M, bestaande uit 11.4% salaris en 88.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.79% van de aandelen van het bedrijf, ter waarde € 31.27M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.8 jaar en 6.8 jaar.

Belangrijke informatie

Vivek Jain

Algemeen directeur

US$6.8m

Totale compensatie

Percentage CEO-salaris	11.4%
Dienstverband CEO	10.8yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	6.8yrs
Gemiddelde ambtstermijn bestuur	6.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Vivek Jain's beloning veranderd ten opzichte van ICU Medical's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$111m
Jun 30 2024	n/a	n/a	-US$71m
Mar 31 2024	n/a	n/a	-US$59m
Dec 31 2023	US$7m	US$775k	-US$30m
Sep 30 2023	n/a	n/a	-US$28m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$46m
Dec 31 2022	US$6m	US$756k	-US$74m
Sep 30 2022	n/a	n/a	-US$39m
Jun 30 2022	n/a	n/a	US$5m
Mar 31 2022	n/a	n/a	US$41m
Dec 31 2021	US$5m	US$650k	US$103m
Sep 30 2021	n/a	n/a	US$109m
Jun 30 2021	n/a	n/a	US$103m
Mar 31 2021	n/a	n/a	US$94m
Dec 31 2020	US$3m	US$650k	US$87m
Sep 30 2020	n/a	n/a	US$81m
Jun 30 2020	n/a	n/a	US$83m
Mar 31 2020	n/a	n/a	US$87m
Dec 31 2019	US$3m	US$650k	US$101m
Sep 30 2019	n/a	n/a	US$73m
Jun 30 2019	n/a	n/a	US$47m
Mar 31 2019	n/a	n/a	US$55m
Dec 31 2018	US$6m	US$650k	US$29m
Sep 30 2018	n/a	n/a	US$86m
Jun 30 2018	n/a	n/a	US$86m
Mar 31 2018	n/a	n/a	US$18m
Dec 31 2017	US$4m	US$650k	US$69m

Compensatie versus markt: De totale vergoeding ($USD 6.81M ) Vivek } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.90M ).

Compensatie versus inkomsten: De vergoeding van Vivek is gestegen terwijl het bedrijf verliesgevend is.

CEO

Vivek Jain (52 yo)

10.8yrs

Tenure

US$6,810,975

Compensatie

Mr. Vivek Jain has been an Independent Director of Envista Holdings Corporation since April 07, 2020. Mr. Jain has been Chairman and Chief Executive Officer of ICU Medical, Inc. since February 13, 2014. Mr...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Vivek Jain	CEO & Chairman of the Board	10.8yrs	US$6.81m	0.79% € 31.3m
Daniel Woolson	President	less than a year	US$2.21m	0.054% € 2.1m
Brian Bonnell	CFO & Treasurer	4.7yrs	US$4.39m	0.10% € 4.0m
Christian Voigtlander	Chief Operating Officer	6.8yrs	US$4.40m	geen gegevens
Virginia Sanzone	Corporate VP	6.8yrs	US$2.47m	0.018% € 725.2k

6.8yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IC7 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Vivek Jain	CEO & Chairman of the Board	10.8yrs	US$6.81m	0.79% € 31.3m
Elisha Finney	Independent Director	8.8yrs	US$265.14k	0.0087% € 344.6k
Kolleen Kennedy	Independent Director	2.9yrs	US$255.14k	0.0064% € 252.7k
David Hoffmeister	Independent Director	6.8yrs	US$282.14k	0.012% € 489.6k
Laurie Hernandez	Independent Director	3.3yrs	US$255.14k	0.0077% € 305.0k
David Greenberg	Lead Independent Director	9.3yrs	US$296.14k	0.023% € 895.6k
Donald Abbey	Independent Director	6.8yrs	US$255.14k	0.012% € 489.6k

6.8yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IC7 wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).

ICU Medical Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

ICU Medical, Inc. Appoints Daniel Woolson as President

Insider recently sold €369k worth of stock

Insufficient new directors

Chief Operating Officer recently sold €1.2m worth of stock

ICU Medical, Inc., Annual General Meeting, May 15, 2024

ICU Medical, Inc. Announces the Resignation of Bill Seeger as Nominated Director

Recent updates

Third quarter 2024 earnings released: US$1.35 loss per share (vs US$0.30 profit in 3Q 2023)

ICU Medical, Inc. Revises Earnings Guidance for the Year 2024

ICU Medical, Inc. Revises Earnings Guidance for the Year 2024

ICU Medical, Inc. to Report Q3, 2024 Results on Nov 12, 2024

ICU Medical, Inc. Appoints Daniel Woolson as President

Insider recently sold €369k worth of stock

Now 22% undervalued

New minor risk - Share price stability

ICU Medical, Inc. Updates Earnings Guidance for the Fiscal Year 2024

Insufficient new directors

ICU Medical, Inc. to Report Q2, 2024 Results on Aug 07, 2024

ICU Medical, Inc.(NasdaqGS:ICUI) dropped from Russell 1000 Dynamic Index

Chief Operating Officer recently sold €1.2m worth of stock

First quarter 2024 earnings released: US$1.63 loss per share (vs US$0.41 loss in 1Q 2023)

ICU Medical, Inc. Provides Updated Unaudited Earnings Guidance for the Year 2024

ICU Medical, Inc. to Report Q1, 2024 Results on May 07, 2024

ICU Medical, Inc., Annual General Meeting, May 15, 2024

ICU Medical, Inc. Announces the Resignation of Bill Seeger as Nominated Director

Chief Operating Officer recently sold €1.3m worth of stock

ICU Medical, Inc. Announces Resignation of William Seeger from Board of Director and Member of the Audit and Compliance Committee

Full year 2023 earnings released: US$1.23 loss per share (vs US$3.11 loss in FY 2022)

ICU Medical, Inc. to Report Q4, 2023 Results on Feb 27, 2024

ICU Medical, Inc.(NasdaqGS:ICUI) dropped from S&P 400 Health Care (Sector)

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: US$0.30 (vs US$0.55 loss in 3Q 2022)

ICU Medical, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Chief Operating Officer recently sold €825k worth of stock

ICU Medical Inc. Receives FDA Clearance for Plum Duo Infusion Pump and LifeShield Infusion Safety Software

Icu Medical, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: US$0.41 loss per share (vs US$0.31 loss in 2Q 2022)

ICU Medical, Inc. to Report Q2, 2023 Results on Aug 07, 2023

ICU Medical, Inc.(NasdaqGS:ICUI) dropped from Russell Small Cap Comp Growth Index

First quarter 2023 earnings released: US$0.41 loss per share (vs US$1.61 loss in 1Q 2022)

Now 20% undervalued after recent price drop

Full year 2022 earnings released: US$3.11 loss per share (vs US$4.86 profit in FY 2021)

ICU Medical, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.47 profit in 3Q 2021)

ICU Medical, Inc. Reaffirms Earnings Guidance for the Full Year 2022

ICU Medical, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$1.34 profit in 2Q 2021)

ICU Medical, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Corporate VP recently sold €125k worth of stock

First quarter 2022 earnings released: US$1.61 loss per share (vs US$1.12 profit in 1Q 2021)

ICU Medical, Inc. to Report Q1, 2022 Results on May 09, 2022

ICU Medical, Inc., Annual General Meeting, May 17, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ICU Medical, Inc. Provides Earnings Guidance for the Fiscal Year 2022

ICU Medical, Inc. Announces Executive changes, Effective March 18, 2022

ICU Medical, Inc. to Report Q4, 2021 Results on Feb 24, 2022

ICU Medical, Inc. Announces Appointment of William Seeger as Director, Member of Audit and Compliance Committee

ICU Medical, Inc. (NasdaqGS:ICUI) completed the acquisition of Smiths Medical, Inc. from Smiths Group plc (LSE:SMIN).

Insufficient new directors

Third quarter 2021 earnings released: EPS US$1.47 (vs US$1.19 in 3Q 2020)

Corporate VP recently sold €170k worth of stock

Investor sentiment improved over the past week

ICU Medical, Inc. (NasdaqGS:ICUI) entered into an agreement to acquire Smiths Medical Division from Smiths Group plc (LSE:SMIN) for $2.5 billion.

ICU Medical, Inc. Issues Voluntary Nationwide Recall of Aminosyn II 15%, an Amino Acid Injection, Sulfite Free IV Solution Due to the Presence of Particulate Matter

ICU Medical, Inc. Provides Earnings Guidance for the Fiscal Year 2021

Second quarter 2021 earnings released: EPS US$1.34 (vs US$0.91 in 2Q 2020)

ICU Medical, Inc.(NasdaqGS:ICUI) dropped from Russell 1000 Growth Index

Independent Director recently sold €251k worth of stock

Corporate VP recently sold €162k worth of stock

First quarter 2021 earnings released: EPS US$1.12 (vs US$0.81 in 1Q 2020)

Independent Director recently sold €257k worth of stock

Full year 2020 earnings released: EPS US$4.16 (vs US$4.90 in FY 2019)

ICU Medical, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €178

New 90-day high: €174

Revenue beats expectations